Latest Payments News

Noumi Limited has completed its $11.56 million payment towards a $43 million class action settlement, now unconditional following Victorian Supreme Court approval. The payment was made by insurers, activating legal releases for the company.

Bega Cheese Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.06 per share and setting the Dividend Reinvestment Plan price at AUD 5.77 with no discount.

Novatti Group has offloaded its Emersion business to CGP Equity for $500,000, marking a strategic pivot to concentrate on its core payments infrastructure in Australia and New Zealand.

Commonwealth Bank of Australia has updated details for its six-month dividend, confirming a fully franked payout of AUD 2.60 per share with multi-currency payment options and a Dividend Reinvestment Plan.

MyState Limited has confirmed a fully franked ordinary dividend of AUD 0.11 per share for the six months ending June 2025, alongside a dividend reinvestment plan priced at AUD 4.195 per share.

4DMedical has won a crucial US Medicare reimbursement for its CT, VQ™ lung imaging software, paving the way for rapid adoption across American hospitals. This milestone follows FDA clearance and promises to transform lung diagnostics with safer, faster scans.

COG Financial Services is set to broaden its salary packaging and novated leasing footprint across Australia through the $40 million acquisition of EasiFleet. This strategic move positions COG for upcoming government contracts in key states.

Mantle Minerals has announced a proposed capital return of $0.001 per share, subject to shareholder approval at its upcoming AGM, potentially distributing over $6 million back to investors.

Citigroup Global Markets Australia has declared a fully franked AUD 0.30 dividend for its ORG CitiFirst Self-Funding Instalment MINIs, reducing outstanding loan amounts and aligning dividend dates with ORG ordinary shares.

Lendlease Group has confirmed its ordinary dividend for the financial year ending June 2025, alongside the Dividend Reinvestment Plan price and currency arrangements for payments to investors in Australia, New Zealand, and the UK.

OM Holdings reported steady revenue of US$309.3 million in 1H 2025 despite a sharp EBITDA decline and net loss, while maintaining a strong cash position and advancing sustainability goals.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.